Smart Drug-Delivery Systems for Cancer Nanotherapy

Curr Drug Targets. 2018 Feb 19;19(4):339-359. doi: 10.2174/1389450117666160527142544.

Abstract

Background: Despite all the advances achieved in the field of tumor-biology research, in most cases conventional therapies including chemotherapy are still the leading choices. The main disadvantage of these treatments, in addition to the low solubility of many antitumor drugs, is their lack of specificity, which leads to the occurrence of severe side effects due to nonspecific drug uptake by healthy cells.

Objective: The purpose of this manuscript is to review and analyze the recent progress made in cancer nanotherapy.

Results: Progress in nanotechnology and its application in medicine have provided new opportunities and different smart systems. Such systems can improve the intracellular delivery of the drugs due to their multifunctionality and targeting potential. First, we provide a global overview of cancer and different smart nanoparticles currently used in oncology. Then, we analyze in detail the development of drug-delivery strategies in cancer therapy, focusing mainly on the intravenously administered smart nanoparticles. Finally, we discuss the challenges, clinical trials, marketed nanomedicines and future directions of the nanotherapy applied to cancer treatment.

Conclusion: In this review, we have evidenced the tremendous potential that smart drug-delivery systems have to enhance the therapeutic effect of current standard treatment modalities, including chemotherapies and radiotherapies.

Keywords: Nanomedicine; cancer therapy; drug delivery; nanotechnology; radiotherapy.; smart nanoparticle.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Administration, Intravenous
  • Antineoplastic Agents / administration & dosage*
  • Antineoplastic Agents / chemistry
  • Clinical Trials as Topic
  • Drug Carriers / chemistry
  • Drug Delivery Systems / methods*
  • Humans
  • Nanoparticles / chemistry*
  • Neoplasms / drug therapy*

Substances

  • Antineoplastic Agents
  • Drug Carriers